3
|
van der Heijde D, Kartman CE, Xie L, Beattie S, Schlichting D, Mo D, Durez P, Tanaka Y, Fleischmann R. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. J Rheumatol 2021; 49:133-141. [PMID: 34526397 DOI: 10.3899/jrheum.210346] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2021] [Indexed: 10/20/2022]
Abstract
OBJECTIVE To evaluate the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active rheumatoid arthritis (RA). METHODS Patients completed 1 of 3 phase III baricitinib trials (ClinicalTrials.gov: NCT01711359, NCT01710358, or NCT01721057) and entered the long-term extension RA-BEYOND (NCT01885078), in which patients received once-daily 4 mg or 2 mg baricitinib. Across these trials, patients initially receiving methotrexate (MTX) or adalimumab (ADA) switched to baricitinib 4 mg at Week 52. Patients initially receiving placebo (PBO) switched to baricitinib 4 mg at Week 24. Radiographs were scored at baseline and Years 2, 3, 4, and 5. Change from baseline in van der Heijde modified total Sharp score (ΔmTSS) was computed. RESULTS Overall, 2125 of 2573 (82.6%) randomized patients entered RA-BEYOND; 1837 of 2125 (86.4%) entered this analysis. From Years 3 to 5, higher proportions of disease-modifying antirheumatic drug (DMARD)-naïve patients on initial baricitinib (monotherapy or with MTX) had no progression vs initial MTX (ΔmTSS ≤ 0 at Year 5: 59.6% baricitinib 4 mg; 66.2% baricitinib 4 mg + MTX; 40.7% MTX). Higher proportions of patients with inadequate response (IR) to MTX on initial baricitinib or ADA vs PBO had no progression (ΔmTSS ≤ 0 at Year 5: 54.8% baricitinib 4 mg; 55.0% ADA; 50.3% PBO). Higher proportions of patients with conventional synthetic DMARD-IR on initial baricitinib 4 mg had less progression vs initial PBO or baricitinib 2 mg (ΔmTSS ≤ 0 at Year 5: 66.7% baricitinib 4 mg; 58.2% baricitinib 2 mg; 60.0% PBO). CONCLUSION Oral baricitinib maintained lower levels of radiographic progression than initial conventional synthetic DMARD or PBO through 5 years in patients with active RA.
Collapse
Affiliation(s)
- Désirée van der Heijde
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Cynthia E Kartman
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Li Xie
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Scott Beattie
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Douglas Schlichting
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Daojun Mo
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Patrick Durez
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Yoshiya Tanaka
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| | - Roy Fleischmann
- Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib, under license from Incyte Corporation. All costs associated with the development of this manuscript, including article processing charges and medical writing and editing services, were funded by Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; C.E. Kartman, RN, S. Beattie, PhD, D. Mo, MD, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA; L. Xie, MS, Eli Lilly and Company, Indianapolis, Indiana, now with EQRx, Cambridge, Massachusetts, USA; D. Schlichting, RN, PhD, Eli Lilly and Company, Indianapolis, Indiana, now with Janssen Pharmaceuticals, Spring House, Pennsylvania, USA; P. Durez, MD, PhD, Université Catholique de Louvain-Saint Luc, Brussels, Belgium; Y. Tanaka, MD, PhD, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; R. Fleischmann, MD, MACR, Metroplex Clinical Research Center/ University of Texas Southwestern Medical Center, Dallas, Texas, USA. DvdH has received consulting fees from AbbVie, Astellas, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB Pharma; and is the Director of Imaging at Rheumatology BV. PD has received speaker's fees from BMS, Celltrion, Eli Lilly and Company, and Sanofi. YT has received speaker's fees from AbbVie, Asahi-kasei, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Gilead, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, YL Biologics; and grant/research support from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, and Takeda. RF has received consultancy fees and research/grant support from AbbVie, Amgen, Eli Lilly, GSK, Gilead, Novartis, Pfizer, Regeneron, Samumed, Sanofi, Selecta, TEVA, UCB, and Viela. CEK, SB, and DM are employees and shareholders of Eli Lilly. LX and DS are previous employees of Eli Lilly and hold stocks in the company. Address correspondence to C.E. Kartman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. . Accepted for publication September 2, 2021
| |
Collapse
|